An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis

Exclusion Criteria

• •Must have reached at least 20% improvement in SJC and/or TJC (66/68 counts) compared to Week 0 at Week 24 for subjects participating in the preceding Phase IIb ALX0061 C201 study, or at Week 12 for subjects participating in the preceding Phase IIb ALX0061-C202 study
• •Female subjects of childbearing potential (excluding postmenopausal women, sterilized, ovariectomized, and hysterectomized women) must agree to use 2 generally accepted adequate contraceptive methods of which 1 is a barrier method (e.g., hormonal contraception stabilized for at least 1 month \[oral, patch, depot, injectable, vaginal ring\] in combination with condom by partner) or should agree upon continuous abstinence from heterosexual contact from screening/baseline until at least 6 months after last dosing. Male subjects must use condoms for the duration of the study and for at least 6 months after last administration of study drug.
• •Ability to comprehend and willingness to sign the informed consent form (ICF).
• •An understanding of and ability and willingness to adhere to the study visit schedule and other protocol requirements.
• •Received TCZ during the previous Study ALX0061-C202.
• •Received any prohibited treatment during the previous Phase IIb studies (ALX0061-C201 or ALX0061-C202.
• •Diagnosis of or suspicion of a serious infection (requiring parental antibiotics and/or hospitalization) or tuberculosis during the preceding study.
• •Diagnosis of malignancy or demyelinating disease during the preceding study.
• •Any active or recurrent viral infection that made the subject unsuitable for the study based on the Investigator's clinical assessment, including recurrent/disseminated herpes zoster.
• •Diagnosis of congestive heart failure class III or IV (as defined by the New York Heart Association), unstable angina pectoris, myocardial infarction, and/or cerebrovascular accident during the preceding study.
• •Abnormality in laboratory test results observed at the Week 22 visit for subjects participating in the preceding Phase IIb ALX0061-C201 study, or observed at the Week 10 visit for subjects participating in the preceding Phase IIb ALX0061-C202 study:
• •1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels ≥ 2 times the upper limit of normal (ULN).
• •2. Hemoglobin levels ≤ 85 g/L (8.5 g/dL).
• •3. Platelet count ≤ 75 x 109/L (75,000 cells/mm³).
• •4. Absolute neutrophil count \< 1.5 x 109/L.
• •5. Serum creatinine levels ≥ 1.5 mg/dL (133 μmol/L).
• •6. Any other clinically significant abnormal laboratory result as evaluated by the Investigator.